Skip to main content

Table 2 Hematological and non-hematological adverse events

From: Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma

Adverse events Grade 1 Grade 2 Grade 3 Grade 4
Number of cycles in which hematological adverse events were reported (n = 283)
Neutropenia 11 (4%) 28 (10%) 58 (20%) 113 (40%)
Thrombocytopenia 70 (25%) 48 (17%) 17 (6%) 10 (4%)
Anemia 85 (30%) 34 (12%) 11 (4%) 0
Febrile neutropenia 0 0 15 (5%) 0
Number of patients with hematological adverse events (n = 49)
Neutropenia 2 (4%) 3 (6%) 15 (31%) 26 (53%)
Thrombocytopenia 12 (24%) 10 (20%) 4 (8%) 1 (2%)
Anemia 17 (35%) 12 (24%) 9 (18%) 0
Febrile neutropenia 0 0 6 (12%) 0
Number of patients with non-hematological adverse events (n = 49)
Liver function abnormalities 5 (10%) 1 (2%) 4 (8%) 0
Infection 2 (4%) 6 (12%) 8 (16%) 0
Fatigue 2 (4%) 3 (6%) 0 0
Vomiting 3 (6%) 1 (2%) 0 0
Diarrhea 2 (4%) 1 (2%) 0 0
Hypoalbuminemia 5 (10%) 0 0 0
Hypokalemia 4 (8%) 0 0 0
Heart failure 0 1 (2%) 0 0
Atrial fibrillation 0 1 (2%) 0 0
Neurological 2 (4%) 0 0 0